Skip to main content

Advertisement

Table 3 Comparison of Tumour-infiltrating Lymphocyte Subsets in Primary Breast Tumours and Pre-NAC(a)ALN(b) Metastatic Tumours in Women with LLABCs(c)

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

Lymphocyte Subsets (n = 20) Primary Tumours in Breast Median (Range)(d) Metastatic Tumours in ALNs(b) Median (Range)(d) P Value(e)(Primary Versus Metastases)
CD4+ 12.8 (0.6-166.2) 26.1 (0.6-157.4) 0.313
CD8+ 27.4 (0.4-112.6) 37.1 (0.4-160.8) 0.117
FOXP3+ 5.5 (0.4-96.8) 7.2 (1.0-73.6) 0.026f
CTLA-4+ 0.4 (0.0-2.2) 0.8 (0.0-11.6) 0.036f
CD56+ 0.8 (0.0-3.2) 1.5 (0.0-26.8) 0.006f
CD8+:FOXP3+ ratio 3.91 (0.18-45.00) 3.29 (0.40-21.92) 0.167
  1. (a)NAC: Neoadjuvant chemotherapy: (b)ALNs: Axillary lymph nodes (corresponding ipsilateral); (c)LLABCs: Large and locally advanced breast cancers; (d)Average cell count per 400× high-power field (see Materials and Methods); (e)Wilcoxon signed rank test; fStatistically significant